Compare IIF & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IIF | EMBC |
|---|---|---|
| Founded | 1993 | 1924 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 206.3M | 200.5M |
| IPO Year | N/A | 2021 |
| Metric | IIF | EMBC |
|---|---|---|
| Price | $22.30 | $3.13 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $18.50 |
| AVG Volume (30 Days) | 35.4K | ★ 2.1M |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | ★ 13.94% | 6.88% |
| EPS Growth | N/A | ★ 20.90 |
| EPS | N/A | ★ 0.67 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.17 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $4.64 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.83 | $2.77 |
| 52 Week High | $28.37 | $15.55 |
| Indicator | IIF | EMBC |
|---|---|---|
| Relative Strength Index (RSI) | 59.45 | 27.72 |
| Support Level | $21.75 | $3.02 |
| Resistance Level | $22.46 | $3.48 |
| Average True Range (ATR) | 0.41 | 0.17 |
| MACD | 0.13 | 0.15 |
| Stochastic Oscillator | 69.61 | 17.31 |
Morgan Stanley India Investment Fund, Inc. is the United States based non-diversified, closed-end management investment company. Its investment objective is to achieve long-term capital appreciation through investment in equity securities of Indian Issuers. The company's portfolio of investments consists of the investment in different sectors such as auto components, banks, capital markets, construction and engineering, pharmaceuticals and others.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.